RegulationAccelerated Approval (United States), Orphan Drug (United States), Orphan Drug (European Union), Conditional marketing approval (China), Orphan Drug (Japan), Orphan Drug (South Korea), Orphan Drug (Australia), Overseas New Drugs Urgently Needed in Clinical Settings (China), Emergency Use Authorization (China), Orphan Drug (Switzerland), Conditional marketing approval (Israel), Priority Review (United States), Priority Review (China)

Structure/Sequence

Molecular FormulaC41H44N4O10S

InChIKeyYDDMIZRDDREKEP-HWTBNCOESA-N

CAS Registry497871-47-3

Clinical Trials associated with Lurbinectedin

NCT07153055

/ RecruitingPhase 1/2IIT

Phase I/II Trial of Lurbinectedin With Osimertinib in Transformed Small Cell Lung Cancer

This open-label, Phase I/II trial is studying the safety and effectiveness of an experimental drug combination, lurbinectedin with osimertinib, against a rare type of cancer known as transformed small cell lung cancer (SCLC).

Start Date01 Aug 2026

Sponsor / Collaborator

Indiana University

[+1]

NCT07459634

/ Not yet recruitingPhase 2

A Phase 2, Multicenter, Open-Label, Single-Arm Study of Lurbinectedin in Combination With Durvalumab as First-line Maintenance Therapy in Participants With Extensive-Stage Small-Cell Lung Cancer Following Induction Treatment With Platinum Based Chemotherapy and Durvalumab

The purpose of this study is to evaluate the efficacy and safety of lurbinectedin in combination with durvalumab for the treatment of participants with extensive stage small cell lung cancer (ES-SCLC) whose disease has not progressed after first line (1L) induction therapy.

Start Date12 Jun 2026

Sponsor / Collaborator

Jazz Pharmaceuticals Plc

[+1]

NCT07640932

/ Not yet recruitingPhase 2IIT

Lurbinectedin in Combination With Paclitaxel Versus Paclitaxel for Patients With Previously Treated Small Cell Lung Cancer: Randomized, Phase II, Open-label, Multi-center, Prospective Trial(LUPINE)

This clinical trial is designed to compare and evaluate the efficacy and safety of the combination therapy of Lurbinectedin plus Paclitaxel (Combination Arm) versus Paclitaxel monotherapy (Monotherapy Arm) in patients with extensive-stage small-cell lung cancer whose disease has progressed after first-line chemotherapy.

Start Date01 Jun 2026

Sponsor / Collaborator

Yonsei University

100 Clinical Results associated with Lurbinectedin

100 Translational Medicine associated with Lurbinectedin

100 Patents (Medical) associated with Lurbinectedin

200

Literatures (Medical) associated with Lurbinectedin

01 Jul 2026·LUNG CANCER

Comparative efficacy of tarlatamab and second-line therapies in extensive-stage small cell lung cancer: A network meta-analysis

Article

Author: Pundole, Xerxes ; Pastel, Malaika ; Wang, Jessie ; Zhang, Yuehan ; Takundwa, Rumbidzai ; Dirnberger, Franziska ; Chai, Xinglei ; Blackhall, Fiona ; Yu, Youfei ; Gomez-Randulfe, Igor ; Anderson, Erik S ; Yang, Hongbo

INTRODUCTION:

In the phase 3 DeLLphi-304 trial, tarlatamab demonstrated significant clinical benefit over second-line (2L) standard-of-care (SOC) chemotherapy options (topotecan, lurbinectedin, amrubicin) in patients with previously treated extensive-stage small cell lung cancer (ES-SCLC). However, the relative efficacy between tarlatamab and other available 2L regimens, such as platinum rechallenge or cyclophosphamide, doxorubicin, and vincristine (CAV), remains unassessed.

MATERIALS AND METHODS:

A Bayesian network meta-analysis evaluated overall survival (OS), progression-free survival (PFS), overall response rate (ORR), and disease control rate (DCR) between tarlatamab and historical 2L ES-SCLC treatments. Analyses were conducted in the overall 2L population and platinum-sensitive subgroup (chemotherapy-free interval [CFI] ≥90 days).

RESULTS:

In the overall 2L population, tarlatamab was associated with significantly longer OS versus all comparators (hazard ratio [HR] range: 0.50 [95% credible interval (CrI): 0.35, 0.70] to 0.62 [0.45, 0.87]), and favorable PFS (HR range: 0.68 [0.49, 0.93] to 0.94 [0.71, 1.25]). Tarlatamab also significantly improved ORR versus CAV, topotecan, irinotecan, and dinutuximab + irinotecan (odds ratio [OR] range: 2.58-3.76), and improved DCR versus CAV (OR: 2.35), while ORR/DCR differences with other comparators were not significant. In patients who were platinum-sensitive, tarlatamab similarly conferred a significant OS benefit over all comparators (HR range: 0.51 [0.31-0.84] to 0.63 [0.40-0.98]), including platinum rechallenge, although PFS, ORR, and DCR differences were not significant.

DISCUSSION:

Tarlatamab demonstrated statistically significant and clinically meaningful improvement in OS compared with all currently available 2L treatments for ES-SCLC in the overall 2L population and platinum-sensitive subgroup, supporting its potential as a new SOC.

01 Jun 2026·American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting

Updates in Small Cell Lung Cancer Treatment: No Longer Too Small to Ignore—A Review of Recent Therapeutic Advances

Review

Author: Dyer, Patrick ; Manochakian, Rami ; Arya, Yajur ; Reguart, Noemi ; Hegi-Johnson, Fiona

Lung cancer remains the leading cause of cancer-related mortality worldwide. Although small cell lung cancer (SCLC) accounts for a smaller percentage of lung cancer cases, it has remained a significant contributor to the overall mortality burden because of its inherently aggressive nature. Over several years, and until recently, there have been no major breakthroughs in the management of SCLC. Concurrent chemoradiation with platinum doublet chemotherapy has remained the mainstay of treatment in limited-stage disease, with chemotherapy being the main and only treatment in extensive stage. Despite having an initial good response to those treatments in most patients, progression of cancer has been nearly inevitable, with no additional effective therapeutic options, and the majority of patients with SCLC dying of their disease. Fortunately, the last decade has witnessed some major scientific advances addressing the huge unmet needs in the realm of SCLC management and ushered in renewed hope in the lung cancer community. From approval of immune checkpoint inhibitors and lurbinectedin, a newer chemotherapy agent, to novel immunotherapies such as tarlatamab, a DLL3-CD3 bispecific T-cell engager, and other upcoming promising drugs, the therapeutic armamentarium for SCLC is steadily expanding. In this study, we review the current landscape of both systemic therapy as well as radiation therapy for SCLC, with a focus on major developments over the past decade, current standards of care, and novel therapeutics that are expected to revolutionize the treatment of this aggressive malignancy.

17 Apr 2026·BRITISH JOURNAL OF HOSPITAL MEDICINE

Lambert-Eaton Myasthenic Syndrome During Immunotherapy in Extensive-Stage Small-Cell Lung Cancer: A Case Report.

Article

Author: Feng, Yunyin ; Yang, Yan ; Ding, Liren

AIMS/BACKGROUND:

Lambert-Eaton myasthenic syndrome (LEMS) is a rare autoimmune disorder of the neuromuscular junction that is frequently associated with small-cell lung cancer (SCLC). It is characterized by proximal muscle weakness, reduced deep tendon reflexes, and autonomic symptoms, all of which can significantly impair quality of life and complicate oncologic management. Early recognition and timely intervention are crucial to improving clinical outcomes.

CASE PRESENTATION:

We report a case of a 76-year-old man with extensive-stage SCLC and chronic renal insufficiency whose LEMS worsened during durvalumab immunotherapy. Despite continued chemotherapy and immunotherapy, his symptoms progressively worsened. Chemotherapy failed to improve his neurological condition, with subsequent recurrent episodes of muscle weakness. Subsequent administration of intravenous immunoglobulin (IVIG) combined with pyridostigmine led to marked neurological improvement and restoration of muscle strength to grade 5, enabling continuation of antitumor therapy. The patient subsequently received three cycles of second-line lurbinectedin chemotherapy, during which inflammatory responses, anemia, and venous thrombosis developed but were effectively managed with supportive treatment.

RESULTS:

Following chemotherapy and immunotherapy, the patient's limb muscle strength recovered to grade 5, followed by recurrent muscle weakness symptoms. Hematologic and biochemical parameters gradually normalized, and inflammatory markers returned to baseline. At discharge, his clinical condition was stable.

CONCLUSION:

This case highlights the importance of early recognition and standardized management of paraneoplastic LEMS in enhancing functional recovery and enabling the safe continuation of antitumor therapy.

193

News (Medical) associated with Lurbinectedin

17 Jun 2026

·www.biospace.com

Jazz strikes new chord with AbCellera in T cell engager pact that could top $2.4B

Getty Images/ seamartini Jazz Pharmaceuticals is diversifying its oncology strategy, orchestrating a new antibody deal with AbCellera that offers $56 million upfront, plus $792 million in biobucks for each of the three initial programs. Jazz Pharmaceuticals is banding together with AbCellera, paying $56 million cash and offering up to some $2.46 billion in total to develop next-generation T cell engagers for hard-to-treat cancers. The collaboration features AbCellera’s multispecific T cell engager (TCE) platform, science that will be fine-tuned in hopes of creating candidates for multiple gastrointestinal (GI) cancers and other solid tumors for which current treatments fall flat. AbCellera will perform discovery and early-stage research for two initial programs, with plans to start a third discovery program in the next year, according to a Wednesday release . For each program, Jazz can opt in for a fee that would grant the biopharma exclusive rights to the candidate. Should Jazz exercise its option, AbCellera could be in line to receive up to $792 million in milestone payments per program, plus tiered royalties. For the work on the first two programs, Canada-based AbCellera will receive $56 million upfront. The biotech will get another $28 million when work on the third program begins. Under the terms of the deal, the partners can also tack on two additional programs, though potential payments for these were not disclosed. “This research collaboration with AbCellera directly aligns with Jazz’s rare disease strategy, expanding our focus on GI cancers and building on our existing expertise in oncology,” Jazz Chief Scientific Officer Josh Allen said in the release. “We look forward to collaborating with AbCellera to progress potential best-in-class TCE multispecific antibodies for GI cancers and other solid tumors into clinical development and to develop meaningful innovation for patients.” For Truist analysts, the move underscores Jazz’s growing focus on GI cancers. The expansion builds off Ziihera, a bispecific HER2-directed antibody that has secured priority review for a label expansion into first-line HER2+ gastroesophageal adenocarcinoma, with an FDA decision expected on or by Aug. 25. Stomach cancer Jazz’s Ziihera Shows ‘Practice-Changing’ Efficacy in Stomach Cancer Jazz’s Ziihera and BeOne’s Tevimbra plus chemotherapy led to what Truist Securities dubbed one of the strongest overall survival signals ever reported in a type of gastroesophageal cancer. January 7, 2026 · 2 min read · Tristan Manalac Read more “We view continued external BD as reinforcing the balanced-portfolio thesis as JAZZ’s onco lean-in and diversification effort has been lively,” Truist wrote in a Wednesday morning note. “While this deal brings additional oncology flavor to the JAZZ platform, we continue to anticipate recurring BD activity in rare disease spaces,” the analysts added. The move also comes directly after Jazz’s alkylating drug Zepzelca failed to improve overall survival for patients with relapsed metastatic small cell lung cancer in a Phase 3 trial last week. The study brings a second line expansion into question, Truist analysts said in a June 12 note, adding, however, that they see the first-line indication as the primary growth driver. Now Jazz will have access to AbCellera’s platform, which includes proprietary panels of CD3-binding antibodies and rapid testing systems to help design multispecific drugs. “Building on years of experience in TCEs, we are pleased to partner with Jazz Pharmaceuticals to leverage AbCellera’s differentiated TCE platform to bring forward novel cancer treatments for GI cancers and other solid tumors,” AbCellera founder and CEO Carl Hansen said in a prepared statement. AbCellera has also teamed up with AbbVie, last year expanding an existing deal to include TCEs for oncology.

Phase 3Priority Review

16 Jun 2026

·www.prnewswire.com

Jazz Pharmaceuticals Provides Update on Zepzelca® (lurbinectedin) Phase 3 LAGOON Trial in Second-Line Small Cell Lung Cancer

June 12, 2026 -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced top-line results from the Phase 3 LAGOON trial, conducted by PharmaMar, evaluating Zepzelca® (lurbinectedin) in patients with relapsed (second-line) metastatic small cell lung cancer (SCLC). The trial did not meet its primary endpoint of overall survival (OS) evaluating Zepzelca as monotherapy or in combination with irinotecan compared to investigators' choice of topotecan or irinotecan. No new safety signals were identified with Zepzelca monotherapy or in combination with irinotecan, and the overall safety profiles of the investigational arms were consistent with the known safety profile of each agent. "Relapsed SCLC is an aggressive cancer with a poor prognosis and patients continue to need treatment options, including in later lines of therapy. We thank the investigators, trial sites and patients who were involved in the LAGOON trial, along with our partner, PharmaMar," said Rob Iannone, M.D., M.S.C.E., executive vice president, global head of research and development, and chief medical officer of Jazz Pharmaceuticals. "Zepzelca is an important treatment in SCLC and, based on the strength of the IMforte trial results, we believe its most beneficial use is in the first-line maintenance setting in combination with immunotherapy given the rapid progression of metastatic SCLC after first-line chemotherapy induction." The full U.S. approval of Zepzelca in 2025 is based on the Phase 3 IMforte trial, which evaluated Zepzelca in combination with atezolizumab as first-line maintenance treatment for patients with extensive-stage SCLC. In the IMforte trial, the Zepzelca and atezolizumab combination demonstrated a statistically significant improvement in the primary endpoints of OS and progression-free survival (PFS), as assessed by an independent review facility, compared to treatment with atezolizumab alone. The Zepzelca and atezolizumab combination reduced the risk of disease progression or death by 46% and the risk of death by 27%, compared to atezolizumab maintenance therapy alone. The LAGOON results are distinct from the IMforte trial and do not impact Zepzelca's approval in the first-line maintenance setting. The company has shared the LAGOON results with the FDA and will discuss next steps with the agency regarding its post-marketing requirements for the Zepzelca second-line indication. The study results do not impact the company's 2026 guidance. The LAGOON trial included a broader patient population than the Phase 2 pivotal trial that supported the second-line accelerated approval, including patients with a history of CNS involvement. Efficacy of Zepzelca in the subset of patients without a history of CNS involvement was more comparable to the control arm, which performed better than historical precedent. The overall safety profile for Zepzelca was favorable relative to the control arm. Treatment-related adverse events (TRAE) were 78.5% with Zepzelca, 95% with Zepzelca + irinotecan, and 93.8% with the control arm. TRAEs Grade ≥ 3 were 35% with Zepzelca, 62.6% with Zepzelca + irinotecan, and 64.4% with the control arm. LAGOON (NCT05153239) is a Phase 3, randomized (1:1:1), multicenter, open-label clinical trial with three arms: one arm to receive lurbinectedin 3.2 mg/m2 as monotherapy (the approved dose in the U.S.), the second arm to receive lurbinectedin 2.0 mg/m2 in combination with irinotecan 75 mg/m2, and the third arm to receive topotecan or irinotecan based on the investigators' choice. The trial was conducted in patients with SCLC, whose disease has progressed following prior platinum-containing chemotherapy with or without anti-PD-1 or anti-PD-L1 agents. The LAGOON trial enrolled 724 patients from more than 200 sites globally, including in the U.S., Canada and Europe. The trial is sponsored by Jazz's partner, PharmaMar. In the U.S., approximately 13 percent of lung cancers are small cell.1 Approximately 30,000 new cases of small cell lung cancer (SCLC) are reported in the U.S. each year.2 The risk for developing SCLC is much higher among current or former tobacco smokers; however, SCLC can also be caused by exposure to secondhand smoke, asbestos, some inhaled chemicals, radiation and air pollution. People with a family history of lung cancer may also be at a higher risk.3 SCLC is an aggressive form of lung cancer and it tends to spread quickly to other parts of the body including the brain, liver and bone.4,5 A large percentage of SCLC patients on treatment briefly achieve a response, although the cancer often returns and is usually more aggressive and resistant to regimens that were previously effective.6 Zepzelca is an alkylating drug that binds guanine residues within DNA. This triggers a cascade of events that can affect the activity of DNA binding proteins, including some transcription factors, and DNA repair pathways, resulting in disruption of the cell cycle and potentially cell death.7 In October 2025, the FDA approved Zepzelca in combination with atezolizumab or atezolizumab and hyaluronidase-tqjs, as maintenance treatment for adults with extensive-stage small cell lung cancer (ES-SCLC) whose disease has not progressed after first-line induction therapy with atezolizumab or atezolizumab and hyaluronidase-tqjs, carboplatin and etoposide. In June 2020, the FDA approved Zepzelca for the treatment of adult patients with metastatic small cell lung cancer (SCLC) with disease progression on or after platinum-based chemotherapy. This indication is approved under accelerated approval based on ORR and DOR. Jazz Pharmaceuticals plc (Nasdaq: JAZZ) is a global biopharma company whose purpose is to innovate to transform the lives of patients and their families. We are dedicated to developing life-changing medicines for people with rare disease — often with limited or no therapeutic options. We have a diverse portfolio of medicines, including leading therapies addressing epilepsies, cancers and sleep disorders. Our patient-focused and science-driven approach powers pioneering research and development advancements across our robust pipeline of innovative therapeutics. Jazz is headquartered in Dublin, Ireland with research and development laboratories, manufacturing facilities and employees in multiple countries committed to serving patients worldwide. 1American Cancer Society. Key Statistics for Lung Cancer. https://www.cancer.org/cancer/types/lung-cancer/about/key-statistics.html. Updated January 13, 2024. Accessed June 2026. 2 National Organization for Rare Diseases. Small cell lung cancer. https://rarediseases.org/rare-diseases/small-cell-lung-cancer/. Updated 2019. Accessed June 2026. 3 American Cancer Society. Lung Cancer Risk Factors. https://www.cancer.org/cancer/types/lung-cancer/causes-risks-prevention/risk-factors.html. Updated January 29, 2024. Accessed June 3, 2026. 4 Cleveland Clinic. Small Cell Lung Cancer. https://my.clevelandclinic.org/health/diseases/6202-small-cell-lung-cancer. Updated September 28, 2022. Accessed June 2026. 5 American Cancer Society. What Is Lung Cancer? https://www.cancer.org/cancer/types/lung-cancer/about/what-is.html. Updated January 29, 2024. Accessed June 2026. 6 Yajur Arya et al. Updates in Small Cell Lung Cancer Treatment: No Longer Too Small to Ignore—A Review of Recent Therapeutic Advances. Am Soc Clin Oncol Educ Book 46, e524964(2026). DOI:10.1200/EDBK-26-524964. Accessed June 2026. 7 ZEPZELCA (lurbinectedin) Prescribing Information. Palo Alto, CA: Jazz Pharmaceuticals, Inc. The content above comes from the network. if any infringement, please contact us to modify.

Clinical ResultDrug ApprovalAccelerated Approval

12 Jun 2026

·firstwordpharma.com

Jazz, PharmaMar's Zepzelca falls short in confirmatory SCLC study

Jazz Pharmaceuticals and PharmaMar's alkylating agent Zepzelca (lurbinectedin) stumbled in the Phase III study meant to secure its full FDA approval in second-line patients with metastatic small-cell lung cancer (SCLC).Topline results from the confirmatory LAGOON trial showed the drug failed on the primary endpoint of overall survival (OS) in patients with relapsed metastatic SCLC, raising doubts about the future of its FDA accelerated approval, granted in 2020. That decision was based on Phase II results showing an overall response rate of 30% with responses lasting a median of 5.1 months.The companies, however, stressed that the setback doesn't affect Zepzelca's newer first-line maintenance indication in extensive-stage SCLC.Still, investor reaction to the news Friday was negative; PharmaMar shares plunged more than 22% in Madrid, while Jazz saw a more modest decline of roughly 2%.'Unexpected OS outperformance'The LAGOON study evaluated Zepzelca as a single agent or in combination with irinotecan, versus investigator's choice of topotecan or irinotecan, in 705 patients with relapsed metastatic SCLC. Median OS was 8.7 months with Zepzelca monotherapy, while it was 10.9 months in the combination arm and 10.7 months in the control group.According to the companies, results may have been affected by an "unexpected OS outperformance of the control arm by 30%," with patients on topotecan achieving median OS of 10.8 months in the study, whereas it was around 8.3 months in recent Phase III trials in this setting.Jazz and PharmaMar also noted that LAGOON enrolled a broader and potentially sicker patient population than the earlier study, including patients with central nervous system (CNS) metastases. If patients didn't have CNS involvement, median OS was 9.6 months for Zepzelca monotherapy and 11.1 months for the combination arm. In the cohort with CNS metastases, median OS results were 7.1 months and 10.5 months for those two arms, respectively.Zepzelca monotherapy did show a more favourable safety profile than the control arm, however, with substantially lower grade ≥3 treatment-related adverse events at 35%, compared to over 60% for the other two arms.Focus shifts to maintenanceThe drug's label was expanded in the US last year to include first-line maintenance in certain extensive-stage SCLC patients when used together with Roche's Tecentriq (atezolizumab) based on data from the Phase III IMforte study. Less than two weeks ago, EU regulators granted their own approval in this indication.PharmaMar noted that LAGOON targets "a different population in a different setting of SCLC" than IMforte, and therefore Friday's setback won't impact that approval.Jazz highlighted that distinction as well. "Based on the strength of the IMforte trial results, we believe [Zepzelca's] most beneficial use is in the first-line maintenance setting in combination with immunotherapy given the rapid progression of metastatic SCLC after first-line chemotherapy induction," said Rob Iannone, chief medical officer at Jazz.Jazz, which markets Zepzelca in the US, said it will discuss next steps with the FDA regarding its post-marketing requirements for the Zepzelca second-line indication.

Clinical ResultPhase 3ImmunotherapyDrug ApprovalAccelerated Approval

100 Deals associated with Lurbinectedin

External Link

KEGG	Wiki	ATC	Drug Bank
D11644	Lurbinectedin	L01XX	DB12674

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Extensive stage Small Cell Lung Cancer	United States	Jazz Pharmaceuticals Ireland Ltd.	02 Oct 2025
Small Cell Lung Cancer	United States	Jazz Pharmaceuticals Ireland Ltd.	15 Jun 2020

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Leiomyosarcoma	Phase 3	United States	Pharma Mar SA	21 Sep 2023
Leiomyosarcoma	Phase 3	Austria	Pharma Mar SA	21 Sep 2023
Leiomyosarcoma	Phase 3	Belgium	Pharma Mar SA	21 Sep 2023
Leiomyosarcoma	Phase 3	France	Pharma Mar SA	21 Sep 2023
Leiomyosarcoma	Phase 3	Germany	Pharma Mar SA	21 Sep 2023
Leiomyosarcoma	Phase 3	Italy	Pharma Mar SA	21 Sep 2023
Leiomyosarcoma	Phase 3	Netherlands	Pharma Mar SA	21 Sep 2023
Leiomyosarcoma	Phase 3	Poland	Pharma Mar SA	21 Sep 2023
Leiomyosarcoma	Phase 3	Portugal	Pharma Mar SA	21 Sep 2023
Leiomyosarcoma	Phase 3	Spain	Pharma Mar SA	21 Sep 2023

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04607954 (MC1923, ASCO2026)	Phase 2	Recurrent Lung Small Cell Carcinoma	22	Durvalumab 1500 mg IV plus Lurbinectedin 3.2 mg/m2 IV (Platinum-resistant relapsed extensive-stage small cell lung cancer + Overall cohort)	beoakcexsm(xmolhtjvtv) = coetimxqzp kvssyxpwgk (tqbxptunce, 7.5 - 44.1) View more	Negative	29 May 2026
ASCO2026	Not Applicable	Islet Cell Carcinoma DLL3	54	platinum-based chemotherapy + Atezolizumab	xesbjjygfj(szmcxnsbdx) = ffsgdwtgxz stbbstbadl (kuzropoolb ) View more	Positive	29 May 2026
				platinum-based chemotherapy + Durvalumab	xesbjjygfj(szmcxnsbdx) = gegeksvrsa stbbstbadl (kuzropoolb ) View more
IMforte (AACR2026)	Phase 3	Extensive stage Small Cell Lung Cancer Maintenance	452	Lurbinectedin plus atezolizumab	lfjbjnyenk(gptsdbjncm) = ianbdiaqwo ddxrukmulk (dtjxaogexu ) View more	Positive	20 Apr 2026
				Durvalumab	lfjbjnyenk(gptsdbjncm) = ycwjknqnga ddxrukmulk (dtjxaogexu ) View more
NCT05091567 (IMforte \| IMforte，GO43104, CTgov)	Phase 3	Extensive stage Small Cell Lung Cancer	660	Atezolizumab (Atezolizumab)	vtwthlhdnv(dlfqcacoed) = vjbwmymoyu hidkkppzjv (vhcoinpkdo, bzgpkmrcoq - hmvfgjlsez) View more	-	29 Dec 2025
				Lurbinectedin+Atezolizumab (Atezolizumab+ Lurbinectedin)	vtwthlhdnv(dlfqcacoed) = cqcdxexmkh hidkkppzjv (vhcoinpkdo, gohhpscwoc - xewvyebzno) View more
NCT05091567 (IMforte, ESMO2025) Manual	Phase 3	Extensive stage Small Cell Lung Cancer First line \| Maintenance	483	Lurbinectedin + Atezolizumab	mqivdcvedl(jthgnriqtu) = crvvawcwcq ektrbvkdsj (mkgjgfygnq ) View more	Positive	17 Oct 2025
				Atezolizumab	mqivdcvedl(jthgnriqtu) = fxhutjcvdi ektrbvkdsj (mkgjgfygnq ) View more
NCT05876715 (ESMO2025)	Phase 1/2	Locally Advanced Soft Tissue Sarcoma First line	40	Lurbinectedin + Ipilimumab + Nivolumab (Phase 1)	ghvpnirbjp(vtzdbtaxez) = dquswqjtsn rvjjwegutq (dbuhsvwgnf ) View more	Positive	17 Oct 2025
				Lurbinectedin + Ipilimumab + Nivolumab (Phase 2)	vnmezdufer(efddrikpaq) = qzsaexgpni dzqareudcs (vjqkiswzsf ) View more
NCT05072106 (CTgov)	Phase 1	Advanced Malignant Solid Neoplasm	11	Lurbinectedin+Bosentan (Bosentan Co-administration Cycle)	rpjghbkmey(tfajgpheyl) = bwpeqgebul wkhxerxexr (frtkwliqmt, 54.81) View more	-	16 Sep 2025
				Lurbinectedin (Single Agent Lurbinectedin Cycle)	rpjghbkmey(tfajgpheyl) = waeztbyhef wkhxerxexr (frtkwliqmt, 49.56) View more
NCT05063318 (CTgov)	Phase 1	Advanced Malignant Solid Neoplasm	14	lurbinectedin+ITZ (ITZ+LRB)	akqrboqqav(cyerkwivpm) = tklyuzqxmo ctbhgdsqwj (ncxhseanhj, 73.9) View more	-	02 Sep 2025
				LRB (LRB Alone)	akqrboqqav(cyerkwivpm) = pedlyhhigg ctbhgdsqwj (ncxhseanhj, 77.37) View more
NCT04358237 (LUPER, Pubmed \| J Thorac Oncol)	Phase 1/2	Recurrent Lung Small Cell Carcinoma Second line	28	Lurbinectedin + Pembrolizumab	bmwiygifrn(emcerfvusx) = erejbpzupx jeifzlhaon (ysahkalprk, 27.5 - 66.1) View more	Positive	01 Jul 2025
				Lurbinectedin + Pembrolizumab (Platinum-sensitive)	ljprenzirq(ytrhwusicg) = ltwmgbxwbh ewkmqbrrer (vhlvlugwen ) View more
NCT05091567 (IMforte, Pubmed \| Lancet) Manual	Phase 3	Extensive stage Small Cell Lung Cancer First line \| Maintenance	483	Lurbinectedin + Atezolizumab	dzasrtkwex(mrroepmrvy): HR = 0.54 (95% CI, 0.43 - 0.67), P-Value = <0.0001 View more	Positive	01 Jun 2025
				Atezolizumab

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis